Can mapping migrant networks help end neglected tropical diseases?

NCT ID NCT07707817

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a community-designed strategy to deliver preventive chemotherapy to mobile and migrant populations in Nigeria, who often miss treatment for neglected tropical diseases like river blindness and schistosomiasis. Researchers will work with communities to map migration patterns and set up convenient medicine distribution points. The goal is to see if this approach increases treatment coverage and brings these diseases closer to elimination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
preventive chemotherapy medicines (ivermectin, albendazole, praziquantel) delivered through a modified mass administration strategy
What this could lead to
If successful, this approach could help eliminate neglected tropical diseases like river blindness and schistosomiasis in hard-to-reach communities.
What could go wrong
This is an implementation study, not a drug trial, so success depends on community participation and logistics. Results may not apply to other regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHATIC FILARIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Recruitment is done at the Household level in selected communities

    RECRUITING

    Ondo, Ondo, Taraba and Akwa Ibom, Nigeria

    Contact Phone: •••-•••-••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.